LGALS3 cfDNA methylation in seminal fluid as a novel prostate cancer biomarker outperforming PSA
Fuente:
Wiley Open Access
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Artículo Open Access |
| Published: |
Wiley
2024
|
| Subjects: | |
| Online Access: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1867010615044734977 |
|---|---|
| author | Irena Abramovic Ivan Pezelj Leo Dumbovic Lucija Skara Abramovic Tonci Vodopic Stela Bulimbasic Goran Stimac Floriana Bulic‐Jakus Tomislav Kulis Ana Katusic Bojanac Davor Tomas Monika Ulamec Nino Sincic |
| author_facet | Irena Abramovic Ivan Pezelj Leo Dumbovic Lucija Skara Abramovic Tonci Vodopic Stela Bulimbasic Goran Stimac Floriana Bulic‐Jakus Tomislav Kulis Ana Katusic Bojanac Davor Tomas Monika Ulamec Nino Sincic Irena Abramovic Ivan Pezelj Leo Dumbovic Lucija Skara Abramovic Tonci Vodopic Stela Bulimbasic Goran Stimac Floriana Bulic‐Jakus Tomislav Kulis Ana Katusic Bojanac Davor Tomas Monika Ulamec Nino Sincic |
| collection | Wiley Open Access |
| contents | LGALS3 cfDNA methylation in seminal fluid as a novel prostate cancer biomarker outperforming PSA Irena Abramovic Ivan Pezelj Leo Dumbovic Lucija Skara Abramovic Tonci Vodopic Stela Bulimbasic Goran Stimac Floriana Bulic‐Jakus Tomislav Kulis Ana Katusic Bojanac Davor Tomas Monika Ulamec Nino Sincic The Prostate AbstractBackgroundThe unmet challenge in prostate cancer (PCa) management is to discriminate it from benign prostate hyperplasia (BPH) due to the lack of specific diagnostic biomarkers. Contemporary research on potential PCa biomarkers is directed toward methylated cell‐free DNA (cfDNA) from liquid biopsies since epigenetic mechanisms are strongly involved in PCa development.MethodsIn the present research, cfDNA methylation of the LGALS3 gene in blood and seminal plasma of PCa and BPH patients was assessed using pyrosequencing, as well as LGALS3 DNA methylation in tissue biopsies. Liquid biopsy samples were taken from patients with clinical suspicion of PCa, who were subsequently divided into two groups, that is, 42 with PCa and 55 with BPH, according to the histopathological analysis.ResultsStatistically significant higher cfDNA methylation of LGALS3 in seminal plasma of BPH than in PCa patients was detected by pyrosequencing. ROC curve analysis showed that it could distinguish PCa and BPH patients with 56.4% sensitivity and 70.4% specificity, while PSA did not differ between the two patient groups. In contrast, there was no statistically significant difference in LGALS3 cfDNA methylation in blood plasma between the two patient groups. In prostate tumor tissue, there was a statistically significant DNA hypermethylation of LGALS3 compared to surrounding nontumor tissue and BPH tissue.ConclusionsThe DNA hypermethylation of the LGALS3 gene represents an event specific to PCa development. In conclusion, LGALS3 cfDNA methylation in seminal fluid discriminates early PCa and BPH presenting itself as a powerful novel PCa biomarker highly outperforming PSA. 10.1002/pros.24749 http://creativecommons.org/licenses/by-nc/4.0/ |
| doi_str_mv | 10.1002/pros.24749 |
| format | Artículo Open Access |
| id | wiley_oa_10_1002_pros_24749 |
| institution | Wiley Open Access |
| license_str_mv | http://creativecommons.org/licenses/by-nc/4.0/ |
| publishDate | 2024 |
| publisher | Wiley |
| record_format | wiley_oa |
| spellingShingle | LGALS3 cfDNA methylation in seminal fluid as a novel prostate cancer biomarker outperforming PSA Irena Abramovic Ivan Pezelj Leo Dumbovic Lucija Skara Abramovic Tonci Vodopic Stela Bulimbasic Goran Stimac Floriana Bulic‐Jakus Tomislav Kulis Ana Katusic Bojanac Davor Tomas Monika Ulamec Nino Sincic The Prostate LGALS3 cfDNA methylation in seminal fluid as a novel prostate cancer biomarker outperforming PSA Irena Abramovic Ivan Pezelj Leo Dumbovic Lucija Skara Abramovic Tonci Vodopic Stela Bulimbasic Goran Stimac Floriana Bulic‐Jakus Tomislav Kulis Ana Katusic Bojanac Davor Tomas Monika Ulamec Nino Sincic The Prostate AbstractBackgroundThe unmet challenge in prostate cancer (PCa) management is to discriminate it from benign prostate hyperplasia (BPH) due to the lack of specific diagnostic biomarkers. Contemporary research on potential PCa biomarkers is directed toward methylated cell‐free DNA (cfDNA) from liquid biopsies since epigenetic mechanisms are strongly involved in PCa development.MethodsIn the present research, cfDNA methylation of the LGALS3 gene in blood and seminal plasma of PCa and BPH patients was assessed using pyrosequencing, as well as LGALS3 DNA methylation in tissue biopsies. Liquid biopsy samples were taken from patients with clinical suspicion of PCa, who were subsequently divided into two groups, that is, 42 with PCa and 55 with BPH, according to the histopathological analysis.ResultsStatistically significant higher cfDNA methylation of LGALS3 in seminal plasma of BPH than in PCa patients was detected by pyrosequencing. ROC curve analysis showed that it could distinguish PCa and BPH patients with 56.4% sensitivity and 70.4% specificity, while PSA did not differ between the two patient groups. In contrast, there was no statistically significant difference in LGALS3 cfDNA methylation in blood plasma between the two patient groups. In prostate tumor tissue, there was a statistically significant DNA hypermethylation of LGALS3 compared to surrounding nontumor tissue and BPH tissue.ConclusionsThe DNA hypermethylation of the LGALS3 gene represents an event specific to PCa development. In conclusion, LGALS3 cfDNA methylation in seminal fluid discriminates early PCa and BPH presenting itself as a powerful novel PCa biomarker highly outperforming PSA. 10.1002/pros.24749 http://creativecommons.org/licenses/by-nc/4.0/ |
| title | LGALS3 cfDNA methylation in seminal fluid as a novel prostate cancer biomarker outperforming PSA |
| topic | The Prostate |
| url | https://onlinelibrary.wiley.com/doi/10.1002/pros.24749 |